A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes

Lancet. 2003 Jan 18;361(9353):228-30. doi: 10.1016/s0140-6736(03)12256-8.


Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intestinal mucosa and released in response to a meal, is essential for normal glucose homoeostasis. There is much interest in the use of GLP-1 to treat diabetes, since the risk of hypoglycaemia is thought to be low. We report an instance of a 45-year-old woman with a GLP-1 and somatostatin secreting neuroendocrine tumour who presented with reactive hypoglycaemia and hyperglycaemia, but who was subsequently cured by surgery. This case, of a neuroendocrine tumour secreting GLP-1 and causing reactive hypoglycaemia, indicates a potential adverse effect of GLP-1 therapy for diabetes.

Publication types

  • Case Reports

MeSH terms

  • Blood Glucose
  • Carcinoid Tumor / metabolism*
  • Carcinoid Tumor / pathology
  • Carcinoid Tumor / surgery
  • Diabetes Complications*
  • Female
  • Glucagon / metabolism*
  • Glucagon-Like Peptide 1
  • Glucose Tolerance Test
  • Humans
  • Hypoglycemia / complications
  • Hysterectomy
  • Middle Aged
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / surgery
  • Peptide Fragments / metabolism*
  • Protein Precursors / metabolism*
  • Somatostatin / metabolism*


  • Blood Glucose
  • Peptide Fragments
  • Protein Precursors
  • Somatostatin
  • Glucagon-Like Peptide 1
  • Glucagon